TITLE

HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1--Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine

AUTHOR(S)
Gilbert, Peter B.; Ackers, Marta L.; Berman, Phillip W.; Francis, Donald P.; Popovic, Vladimir; Hu, Dale J.; Heyward, William L.; Sinarigil, Faruk; Shepherd, Bryan E.; Gurwith, Marc
PUB. DATE
September 2005
SOURCE
Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p974
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5403 initially HIV-negative volunteers who were monitored for 3 years. The 368 subjects who acquired HIV-1 infection were monitored for 2 years by use of the following postinfection end points: plasma HIV-1 RNA level (viral load), CD4+ lymphocyte count, initiation of antiretroviral therapy (ART), and HIV-1-related clinical outcomes. This article reports the study results that pertain to the effect of vaccination on the postinfection end points. The time until initiation of ART and the time until virologic failure or initiation of ART were similar in the vaccine arm and the placebo arm. The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable between the groups. Evidently, the vaccine did not affect HIV-1 disease progression.
ACCESSION #
17988470

 

Related Articles

  • Editorial [Hot Topic:Antibody Neutralization (Guest Editor: Kelly Stefano Cole)]. Cole, Kelly Stefano; Ross, Ted M. // Current HIV Research;Nov2007, Vol. 5 Issue 6, p505 

    Each year, more than 5 million individuals are newly infected with HIV-1 [1]. To address this, the development of an HIV/AIDS vaccine has remained one of the highest priorities in biomedical research for the last 25 years. During this time, we have witnessed some success with the development of...

  • Symptom Burden in HIV-Infected Adults at Time of HIV Diagnosis in Rural Uganda. Wakeham, Katie; Harding, Richard; Bamukama-Namakoola, Doreen; Levin, Jonathan; Kissa, John; Parkes-Ratanshi, Rosalind; Muzaaya, Godfrey; Grosskurth, Heiner; Lalloo, David G. // Journal of Palliative Medicine;Apr2010, Vol. 13 Issue 4, p375 

    Purpose: This study aimed to measure symptom burden prior to antitetroviral therapy (ART) initiation in a population of adults with low CD4 presenting for human immunodeficiency virus (HIV) care and treatment in Uganda, and to explore the relationship between World Health Organization (WHO)...

  • Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatment-Experienced Patients with HIV-1 Infection. Flandre, Philippe; Chappey, Colombe; Marcelin, Anne Genevieve; Ryan, Kirk; Maa, Jen-Fue; Bates, Mike; Seekins, Daniel; Bernard, Marie Charlotte; Calvez, Vincent; Molina, Jean Michel // Journal of Infectious Diseases;2/1/2007, Vol. 195 Issue 3, p392 

    Objective. We investigated the relationship between human immunodeficiency virus (HIV) phenotypic susceptibility to didanosine and the antiviral activity of didanosine (ddI) in the JAGUAR study. Methods. Baseline plasma HIV phenotypic susceptibility to ddI was assessed using a phenotype assay of...

  • Old vaccine trial draws new scrutiny. McEnery, Regina // VAX; 

    The article offers information related to premature termination of a Phase IIb Human Immunodeficiency Virus (HIV) vaccine trial in the U.S. known as HVTN 505, which has led to the fresh analysis of termination of a Phase IIb study from South Africa which was halted a few months after it started...

  • Inhibition of HIV-1 by Fusion Inhibitors. Eggink, Dirk; Berkhout, Ben; Sanders, Rogier W. // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3716 

    No abstract available.

  • Lymphoid Fibrosis Occurs in Long-Term Nonprogressors and Persists With Antiretroviral Therapy but May Be Reversible With Curative Interventions. Sanchez, Joyce L.; Hunt, Peter W.; Reilly, Cavan S.; Hatano, Hiroyu; Beilman, Gregory J.; Khoruts, Alexander; Jasurda, Jake S.; Ma Somsouk; Thorkelson, Ann; Russ, Samuel; Anderson, Jodi; Deeks, Steven G.; Schacker, Timothy W. // Journal of Infectious Diseases;Apr2015, Vol. 211 Issue 7, p1068 

    Human immunodeficiency virus (HIV) replication causes lymphoid tissue (LT) fibrosis, which causes CD4+ Tcell depletion. It is unknown whether people who spontaneously control HIV replication have LT fibrosis. We measured LT fibrosis and CD4+ T cells in 25 HIV controllers, 10 noncontrollers, 45...

  • Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. Kinloch-de Loes, Sabine; Hoen, Bruno; Smith, Don E.; Autran, Brigitte; Lampe, Fiona C.; Phillips, Andrew N.; Li-Ean Goh; Andersson, Jan; Tsoukas, Christos; Sonnerborg, Anders; Tambussi, Giuseppe; Girard, Pierre-Marie; Bloch, Mark; Battegay, Manuel; Carter, Nick; El Habib, Raphaelle; Theofan, Georgia; Cooper, David A.; Perrin, Luc // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p607 

    Background. Treatment strategies that would induce durable virological control of human immunodeficiency virus (HIV)-1 in the absence of continued antiretroviral therapy (ART) are highly desirable. Methods. We assessed, in a randomized, double-blind, placebo-controlled trial, whether the...

  • One Oral PrEP Arm Discontinued Early in VOICE Trial.  // VAX;Sep2011, Vol. 9 Issue 5, p3 

    The article reports that the clinical trial titled VOICE that was scheduled to be concluded in June 2012 was terminated in September 2011. As stated, the termination was declared when it was examined that the trial would not be able to highlight any difference between daily doses of...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Travel Medicine Advisor;Nov2007, Vol. 17 Issue 11, p2 

    The article reports on the ineffectiveness of HIV vaccine from Merck in a large clinical trial that made the company halt further test vaccinations. A trial which was started in 2004 has identified 24 new HIV infections in the group who received the vaccine compared to 21 infections in the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics